Agemica
1 known investors
Agemica uses AI to rank disease mechanisms across omics data, targets, and safe-drug libraries, then tests predicted drug combinations in ex-vivo human cancer models to measure cancer-cell death, tumor-volume reduction, and healthy-cell safety. The company advances the strongest candidates toward humanized-mouse studies, IND-enabling work, and clinical development in the AI drug discovery and oncology space.
AI & Machine LearningBiotechDeep Tech